BioSpace News Archive

NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced the closing of its initial public offering of 3,133,334 shares of common stock, equivalent with 15,666,670 Korea Depository Receipts (KDRs) priced at KRW 37,500 per share, equivalent with KRW 7,500 per KDRs

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it is part of a collaboration sponsored by Alex’s Lemonade Stand Foundation (ALSF), a leading funder of pediatric cancer research, to develop a drug to potentially treat aggressive childhood cancers including neuroblastoma and medulloblastoma

Repertoire Immune Medicines, a clinical-stage biotech company creating a new category of immune therapies for cancer, autoimmunity and infectious disease, today announced that John Cox, Chief Executive Officer, will present at the Oppenheimer 31st Annual Healthcare Conference on Thursday, March 18, 2021, at 10:00 a.m. ET.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has been invited to present at the Maxim Group LLC and M Vest LLC Inaugural Emerging Growth Virtual Conference

Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that development of the initial production capacity of the Company’s Sawston, UK

InnerScope’s hearIQ App has already received over 440 reviews and has a FIVE-STAR RATING from Apple and Android Device users in just nine days for its free Self-Administered Hearing Test and Direct-to-Consumer Self-Fitting-Self-Adjusting Hearing Devices

Global health service company Cigna has named Lisa Wagamon president of its Medicare Advantage plans in the Carolinas.

The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today released the results of its qualitative and quantitative “Analysis of Professional Work Effort in Molecular Test Interpretation Report.”

Next-generation sequencing (NGS)-based precision oncology provider Geneseeq Technology Inc. (“Geneseeq”), will collaborate with Illumina, Inc. (NASDAQ: ILMN) (“Illumina”) to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer, using Illumina’s NextSeq™ 550Dx sequencing platform

On Friday, the Journal of Personalized Medicine published a first-of-its-kind study applying a quantitative multi-factorial framework to assess the clinical adoption of personalized medicine among a representative sample of 153 health care providers in the United States